Key facts
- Unnatural Products’s last known valuation is $170.0M (Feb 2026).
- It has raised $83.5M across 2 recorded rounds; the latest was Early Stage VC ($25.0M) in Jul 2023.
- Notable investors include Gaingels, Calm Ventures, Abstract Ventures, Wing Venture Capital, SGInnovate — 30 tracked in total.
- Unnatural Products has filed 3 Form Ds with the SEC since 2019, most recently Dec 2023 ($25.0M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Unnatural Products
Funding rounds
2 roundsAbout Unnatural Products
Developer of a computational biology techniques platform designed to engineer peptides that access traditionally undruggable targets. The company's platform uses machine learning to create a parallel chemical synthesis that focuses on the rapid optimization of macrocyclic compounds by harnessing insights from nature, enabling researchers to accelerate the drug discovery process.
- Sector
- Healthcare
- HQ
- Santa Cruz, CA, United States
- Founded
- 2016
- Employees
- 50
- Website
- unnaturalproducts.com/
- Ownership
- Privately Held (backing)
Unnatural Products doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Unnatural Products shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Unnatural Products in its N-PORT filings yet. We sweep new filings monthly.